Breaking News

QIAGEN Expands NGS Assay Portfolio

To add nine GeneRead DNAseq panels

QIAGEN N.V. plans to expand its portfolio of molecular assays used in next-generation sequencing (NGS) for use in clinical research and diagnostics. The current portfolio of nine GeneRead DNAseq panels is being expanded to approximately 20 during the course of 2013.
 
QIAGEN is creating these new gene panels for targeted NGS analysis based on the GeneGlobe portfolio of more than 60,000 annotated molecular assays. These products are designed to be used on any NGS platform, and according to the company, integrate seamlessly into the sample-to-result NGS workflow that includes the QIAGEN GeneReader platform.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters